A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

TheraVasc Inc.26 enrolled

Overview

In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily. Primary endpoints will be safety and pharmacokinetics. Assessment of the study medications affects on pain following treatment will also be recorded.

This is a dose-ranging study to evaluate the safety, pharmacokinetics, and tolerability of multiple doses of an oral, sustained release formulation of sodium nitrite (TV1001sr) in subjects with DNP. The primary objective is to assess the safety and tolerability of multiple doses of twice daily 40 mg and 80 mg TV1001sr compared with placebo over a 12 week treatment period and the pharmacokinetics of the sustained release formulation of sodium nitrite. Secondary objectives are to evaluate the pharmacokinetics and markers of functional improvement including pain questionnaires, quantitative sensory testing and changes in markers of diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Diabetes

Interventions

Sodium nitriteDRUG

Sustained release formulation of sodium nitrite

PlaceboDRUG

Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female subjects must be post-menopausal, sterilized or using suitable birth control * Diagnosis of diabetes (HbA1c \> 6.0) * Diagnosis of diabetic peripheral neuropathy pain in feet * Presence of ongoing diabetic neuropathic for at least 3 months * A pain score of greater than or equal to 4 on the Numerical Pain Rating Scale at screening * Ability to provide written informed consent Exclusion Criteria: * Patients with fibromyalgia or regional pain caused by lumbar or cervical compression * History or diagnosis of significant neurological disease * History and diagnosis of clinically significant psychiatric diseases * Serious liver disease * Poorly controlled diabetes * Hypersensitivity to sodium nitrite or related compounds * Life expectancy \< 6 months * A chronic illness that may increase the risks associated with this study * Active malignancy requiring active anti-neoplastic therapy that will, in the opinion of the investigator, interfere with study treatment or participation * Pregnant or nursing women * Current diagnosis of alcohol or other substance abuse * Current use of sildenafil or other phosphodiesterase Type 5 Inhibitors * History of methemoglobinemia, (met-Hb ≥ 15%) * Subject is involved in litigation or receives worker's compensation * Inability to speak English

Locations (1)

Ohio Pain Clinic

Centerville, Ohio, United States

Outcomes

Primary Outcomes

Reporting of Adverse Events During 12 Week Study Period

The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.

Time frame: 12 weeks

Secondary Outcomes

Pharmacokinetics (Blood Levels of Nitrite)

Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.

Time frame: 1 day

The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.

Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.

Time frame: 12 weeks

Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.

Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.